Tildrakizumab for treating moderate to severe plaque psoriasis : Appraisal consultation committee papers
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.